Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands

Autor:	Ronald A M Damhuis, Pieter J M Joosten, Houke M. Klomp, Egbert F. Smit, Judi N.A. van Diessen, José Belderbos, Joop A de Langen, Koen J. Hartemink, A. A. F. A. Veenhof
Rok vydání:	2020
Předmět:	Adult Male medicine.medical_specialty Lung Neoplasms Adolescent medicine.medical_treatment Stage IIIA Non-Small Cell Lung Cancer Patient characteristics 030218 nuclear medicine & medical imaging Resection Young Adult 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Stage IIIA NSCLC medicine Humans Radiology Nuclear Medicine and imaging Registries Stage (cooking) Pneumonectomy Neoadjuvant therapy Aged Neoplasm Staging Netherlands Aged 80 and over business.industry Hematology General Medicine Middle Aged Neoadjuvant Therapy Cancer registry Survival Rate Treatment Outcome Oncology Lymphatic Metastasis 030220 oncology & carcinogenesis Female Radiology business Chemoradiotherapy
Zdroj:	Acta Oncologica, 59(7), 748-752. TAYLOR & FRANCIS LTD
ISSN:	1651-226X 0284-186X
DOI:	10.1080/0284186x.2020.1757150
Popis:	Introduction: Concurrent chemoradiotherapy remains the main treatment strategy for patients with stage IIIA non-small cell lung cancer (NSCLC); stage cT3N1 or cT4N0-1 may be eligible for surgery and potentially resectable stage IIIA (N2) NSCLC for neoadjuvant therapy followed by resection. We evaluated treatment patterns and outcomes of patients with stage IIIA NSCLC in The Netherlands. Material and Methods: Primary treatment data of patients with clinically staged IIIA NSCLC between 2010 and 2016 were extracted from The Netherlands Cancer Registry. Patient characteristics were tabulated and 5-year overall survival (OS) was calculated and reported. Results: In total, 9,591 patients were diagnosed with stage IIIA NSCLC. Of these patients, 41.3% were treated with chemoradiotherapy, 11.6% by upfront surgery and 428 patients (4.5%) received neoadjuvant treatment followed by resection. The 5-year OS was 26% after chemoradiotherapy, 40% after upfront surgery and 54% after neoadjuvant treatment followed by resection. Clinical over staging was seen in 42.3% of the patients that were operated without neoadjuvant therapy. Conclusion: In The Netherlands, between 2010 and 2016, 4.5% of patients with stage IIIA NSCLC were selected for treatment with neoadjuvant therapy followed by resection. The 5-year OS in these patients exceeded 50%. However, the outcome might be overestimated due to clinical over staging.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a3f3dd63c817de1f84d6a726c702000 https://doi.org/10.1080/0284186x.2020.1757150 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.